86%–90% of pancreatic ductal adenocarcinoma (PDAC) harbor activating mutations in KRAS, which regulate multiple carcinogenic signaling pathways. In order to elucidate the mechanisms underlying KRAS mutation-driven development and progression of PDAC, quantitative proteomics mass-spectrometry(MS) analysis of differential proteins in KRAS-mutant tissues was performed.